AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33740276 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS plus high-dose proton-pump inhibitor (PPI), esomeprazole 40 mg q.i.d. for 3 days
Number of subjects: 27
Study 33740276 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study 34887572 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1944 at doses of 0.1, 0.3, and 0.6 mg/kg, administered via intravenous infusion
Number of subjects: 38
Study 34887572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32677891 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral refeeding (EOR)
Number of subjects: 0
Study 32677891 — intervention group
Group type: COMPARATOR
Intervention: Usual oral refeeding (UOR)
Number of subjects: 0
Study 36180840 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Communication Training (FCT)
Number of subjects: 48
Study 36180840 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster parent training session via telehealth
Number of subjects: 48
Study 36180840 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 48
Study 34052414 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming eye masks generating moist heat at 40 °C for 10 min once daily for 2 weeks
Number of subjects: 86
Study 34052414 — intervention group
Group type: COMPARATOR
Intervention: Non-warming eye masks
Number of subjects: 86
Study 32534647 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg daily
Number of subjects: 861
Study 32534647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 33663581 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure (10-mmHg increase)
Number of subjects: 329237
Study 33663581 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic susceptibility for atrial fibrillation
Number of subjects: 329237
Study 33663581 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers
Number of subjects: 329237
Study 32152335 — intervention group
Group type: EXPERIMENTAL
Intervention: Melinjo seed extract (MSE) 300 mg/day
Number of subjects: 42
Study 32152335 — intervention group
Group type: EXPERIMENTAL
Intervention: Melinjo seed extract (MSE) 500 or 1000 mg/kg/day
Number of subjects: 42
Study 32152335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 36219518 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling followed by PRP (Group A, left side)
Number of subjects: 30
Study 36219518 — intervention group
Group type: COMPARATOR
Intervention: Microneedling alone (Group A, right side)
Number of subjects: 30
Study 36219518 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling followed by PRP (Group B, left side)
Number of subjects: 30
Study 36219518 — intervention group
Group type: COMPARATOR
Intervention: Intradermal injection of PRP (Group B, right side)
Number of subjects: 30
Study 33544361 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 328
Study 33544361 — intervention group
Group type: COMPARATOR
Intervention: Control groups (anxiety-depressive disorders and general population)
Number of subjects: 328
Study 33544361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 328
Study 32492302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-chemotherapy
Number of subjects: 328
Study 32492302 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 328
Study 35526432 — intervention group
Group type: EXPERIMENTAL
Intervention: digital CBT-I
Number of subjects: 1721
Study 35526432 — intervention group
Group type: COMPARATOR
Intervention: Patient Education
Number of subjects: 1721
Study 34008833 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contact CPR training using smart technology (n=31)
Number of subjects: 64
Study 34008833 — intervention group
Group type: COMPARATOR
Intervention: General CPR training (n=33)
Number of subjects: 64
Study 32984080 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (S. dentisani 7746)
Number of subjects: 59
Study 32984080 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 59
Study 36701005 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (2 times weekly, 4 lower body exercises, 3 sets of 6–10 repetitions at 70–85% of 1 repetition maximum)
Number of subjects: 41
Study 36701005 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive control)
Number of subjects: 41
Study 36701005 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 41
Study 33320315 — intervention group
Group type: EXPERIMENTAL
Intervention: iGel
Number of subjects: 63
Study 33320315 — intervention group
Group type: COMPARATOR
Intervention: Cricothyrotomy
Number of subjects: 63
Study 33566173 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy plus involuntary reflexive pelvic floor muscle training
Number of subjects: 96
Study 33566173 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 96
Study 33441145 — intervention group
Group type: EXPERIMENTAL
Intervention: Early standardized acupuncture
Number of subjects: 67
Study 33441145 — intervention group
Group type: COMPARATOR
Intervention: Late standardized acupuncture
Number of subjects: 67
Study 35973626 — intervention group
Group type: EXPERIMENTAL
Intervention: Local prophylactic antibiotic therapy with vancomycin-loaded calcium sulfate beads
Number of subjects: 83
Study 35973626 — intervention group
Group type: COMPARATOR
Intervention: Conventional IV prophylactic antibiotic therapy
Number of subjects: 83
Study 32936370 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (TEP) for 12 weeks including warm-up, strengthening and stretching exercises
Number of subjects: 90
Study 32936370 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise program (TEP) for 12 weeks
Number of subjects: 90
Study 32936370 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 90
Study 32666238 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-inflating bag (SIB)
Number of subjects: 80
Study 32666238 — intervention group
Group type: COMPARATOR
Intervention: T-piece resuscitator (TPR)
Number of subjects: 80
Study 34090689 — intervention group
Group type: COMPARATOR
Intervention: Triple nerve block (ACB + IPACK + ONB + sham LFCNB)
Number of subjects: 0
Study 34090689 — intervention group
Group type: COMPARATOR
Intervention: Quadruple nerve block (ACB + IPACK + ONB + LFCNB)
Number of subjects: 0
Study 34090689 — intervention group
Group type: COMPARATOR
Intervention: Triple nerve block
Number of subjects: 0
Study 34090689 — intervention group
Group type: COMPARATOR
Intervention: Quadruple nerve block
Number of subjects: 0
Study 32507156 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball-hands
Number of subjects: 10
Study 32507156 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball-feet
Number of subjects: 10
Study 32507156 — intervention group
Group type: COMPARATOR
Intervention: Stable surface
Number of subjects: 10
Study 36294287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, trauma-informed service for people with PDA
Number of subjects: 0
Study 36294287 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility study testing the delivery of the intervention protocol
Number of subjects: 0
Study 34938705 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity group (MIG)
Number of subjects: 45
Study 34938705 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity group (LIG)
Number of subjects: 45
Study 34938705 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study 35709647 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 98
Study 35709647 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 98
Study 35709647 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 98
Study 35709647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CT)
Number of subjects: 98
Study 33022574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 33022574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin
Number of subjects: 0
Study 33022574 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of moxidectin, oxibendazole, and pyrantel pamoate
Number of subjects: 0
Study 33022574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (reassessment in June 2020)
Number of subjects: 0
Study 35430922 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical flight surgeon (FS) support
Number of subjects: 16
Study 35430922 — intervention group
Group type: COMPARATOR
Intervention: No telemedical flight surgeon (FS) support
Number of subjects: 16
Study 36170561 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 2 achievement goal questionnaire (3 × 2 AGQ)
Number of subjects: 556
Study 34113000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogenic variants
Number of subjects: 148
Study 34113000 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of Uncertain Significance (VUS)
Number of subjects: 148
Study 34113000 — intervention group
Group type: COMPARATOR
Intervention: Benign variants
Number of subjects: 148
Study 35437881 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxygen therapy (TOT) and standard of care (SOC)
Number of subjects: 29
Study 35437881 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 29
Study 32844309 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Number of subjects: 190
Study 32844309 — intervention group
Group type: COMPARATOR
Intervention: Robotic rehabilitation
Number of subjects: 190
Study 32223076 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lecture followed by CBCT
Number of subjects: 64
Study 32223076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography followed by lecture with skulls
Number of subjects: 64
Study 32223076 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of skulls
Number of subjects: 64
Study 32223076 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT timing
Number of subjects: 64
Study 35973593 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser (SML)
Number of subjects: 266
Study 34438365 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward running (BR) on a negatively inclined treadmill for 5 weeks (9 sessions)
Number of subjects: 15
Study 34438365 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward running (BR) on a negatively inclined treadmill
Number of subjects: 15
Study 33058393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional low dose methylprednisolone (40 mg, once per week for 8 weeks)
Number of subjects: 48
Study 34686126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education on HPV
Number of subjects: 110
Study 34686126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 110
Study 34480521 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-scoring predictive model for multiple synchronous gastric neoplasms (MSGN)
Number of subjects: 1361
Study 34480521 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-scoring predictive model for MSGN
Number of subjects: 1361
Study 32410608 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (intervention group)
Number of subjects: 171
Study 35198922 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) for HIV-TB integration intervention
Number of subjects: 21379
Study 35198922 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 21379
Study 33821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot-supported online questionnaire
Number of subjects: 300
Study 33821454 — intervention group
Group type: COMPARATOR
Intervention: Unassisted online questionnaire (Control)
Number of subjects: 300
Study 35467140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral episiotomy
Number of subjects: 58
Study 33280660 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information while undressed in lithotomy position
Number of subjects: 36
Study 33280660 — intervention group
Group type: COMPARATOR
Intervention: Verbal information once dressed
Number of subjects: 36
Study 34748653 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete digital workflow group (intraoral scanning and split‐file technique)
Number of subjects: 40
Study 34748653 — intervention group
Group type: COMPARATOR
Intervention: Hybrid workflow group (conventional impressions and CAD‐CAM fabricated crowns)
Number of subjects: 40
Study 33435962 — intervention group
Group type: EXPERIMENTAL
Intervention: Good awareness of common NCDs screening during the preconception period
Number of subjects: 636
Study 33435962 — intervention group
Group type: COMPARATOR
Intervention: Formal education
Number of subjects: 636
Study 33435962 — intervention group
Group type: COMPARATOR
Intervention: Planned pregnancy
Number of subjects: 636
Study 33435962 — intervention group
Group type: COMPARATOR
Intervention: ANC follow up
Number of subjects: 636
Study 33435962 — intervention group
Group type: COMPARATOR
Intervention: Having media (radio and/or television) in the house
Number of subjects: 636
Study 34518252 — intervention group
Group type: EXPERIMENTAL
Intervention: Real olfactory stimulation (S2) with mint, grapefruit, and vanilla delivered in puffs over 24 hours.
Number of subjects: 60
Study 34518252 — intervention group
Group type: COMPARATOR
Intervention: Sham olfactory stimulation (S1).
Number of subjects: 60
Study 34518252 — intervention group
Group type: COMPARATOR
Intervention: No olfactory stimulation (S0).
Number of subjects: 60
Study 32638545 — intervention group
Group type: COMPARATOR
Intervention: Front-opening cannula (FOC)
Number of subjects: 43
Study 32638545 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-opening cannula (SOC)
Number of subjects: 43
Study 32120419 — intervention group
Group type: EXPERIMENTAL
Intervention: DVI + Foley
Number of subjects: 100
Study 32120419 — intervention group
Group type: COMPARATOR
Intervention: Foley
Number of subjects: 100
Study 32324197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.016 mg intravitreous bevacizumab
Number of subjects: 59
Study 32324197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.008 mg intravitreous bevacizumab
Number of subjects: 59
Study 32324197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.004 mg intravitreous bevacizumab
Number of subjects: 59
Study 32324197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002 mg intravitreous bevacizumab
Number of subjects: 59
Study 35944894 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (PnOIT)
Number of subjects: 92
Study 35944894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 33508707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 278
Study 33508707 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil (PF)
Number of subjects: 278
Study 33508707 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus capecitabine (PX)
Number of subjects: 278
Study 33508707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (GP, PF, PX)
Number of subjects: 278
Study 32396180 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical footwear (n=111)
Number of subjects: 220
Study 32396180 — intervention group
Group type: COMPARATOR
Intervention: Control footwear (n=109)
Number of subjects: 220
Study 34267006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (scaling and root planning) in group II (n=20)
Number of subjects: 60
Study 34267006 — intervention group
Group type: COMPARATOR
Intervention: Control group III (n=20)
Number of subjects: 60
Study 33221689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicompartmental knee arthroplasty (BCA)
Number of subjects: 48
Study 33221689 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 48
Study 32193093 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossword puzzles as active learning tools
Number of subjects: 224
Study 32193093 — intervention group
Group type: COMPARATOR
Intervention: Routine learning (Control)
Number of subjects: 224
Study 34942090 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-DT vaccine (groups A-C)
Number of subjects: 1800
Study 34942090 — intervention group
Group type: COMPARATOR
Intervention: Vi-TT vaccine (group D)
Number of subjects: 1800
Study 36088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter (quinine) placebo drops
Number of subjects: 297
Study 36088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet (saccharine) placebo drops
Number of subjects: 297
Study 36088659 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste-neutral (water) placebo drops
Number of subjects: 297
Study 32301066 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professional intervention
Number of subjects: 746
Study 34819265 — intervention group
Group type: EXPERIMENTAL
Intervention: Price disclosure (list price)
Number of subjects: 2138
Study 34819265 — intervention group
Group type: EXPERIMENTAL
Intervention: Price disclosure (list price + average out-of-pocket cost)
Number of subjects: 2138
Study 34819265 — intervention group
Group type: COMPARATOR
Intervention: No price disclosure
Number of subjects: 2138
Study 34819265 — intervention group
Group type: EXPERIMENTAL
Intervention: Price disclosure (general)
Number of subjects: 2138
Study 34980810 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (E5564)
Number of subjects: 0
Study 34980810 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011
Number of subjects: 0
Study 32056501 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 60
Study 32056501 — intervention group
Group type: COMPARATOR
Intervention: Laser Ablation (LA)
Number of subjects: 60
Study 33530719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% eyedrops
Number of subjects: 60
Study 33530719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% eyedrops
Number of subjects: 60
Study 33372280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 80
Study 33372280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32019575 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus carvedilol
Number of subjects: 32
Study 32019575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 36027563 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI plus optimal medical therapy
Number of subjects: 700
Study 36027563 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 700
Study 32524538 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game-based therapy (VGBT) using Nintendo® Wii and leap motion controller (LMC) games
Number of subjects: 30
Study 32524538 — intervention group
Group type: COMPARATOR
Intervention: NDT-based upper extremity rehabilitation (control group)
Number of subjects: 30
Study 32562747 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RET, n = 12)
Number of subjects: 24
Study 32562747 — intervention group
Group type: COMPARATOR
Intervention: Active control (CTR, n = 12)
Number of subjects: 24
Study 35700741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glibenclamide (glyburide; BIIB093) treatment
Number of subjects: 399
Study 35700741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 34473304 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training for 10 weeks
Number of subjects: 33
Study 32034070 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD screening followed by patient and provider education
Number of subjects: 1819
Study 32034070 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD screening, education, plus pharmacist comanagement
Number of subjects: 1819
Study 32034070 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1819
Study 35067157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064-nm ps Nd:YAG laser
Number of subjects: 20
Study 35067157 — intervention group
Group type: COMPARATOR
Intervention: 1,064-nm Qs Nd:YAG laser
Number of subjects: 20
Study 32895067 — intervention group
Group type: COMPARATOR
Intervention: WHO hand‐rub diagram
Number of subjects: 0
Study 32895067 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned hand‐rub diagram
Number of subjects: 0
Study 35666967 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed standardized patients (expressing knowledge that antibiotics were not required)
Number of subjects: 227
Study 35666967 — intervention group
Group type: COMPARATOR
Intervention: Uninformed standardized patients (not expressing knowledge that antibiotics were not required)
Number of subjects: 227
Study 33370408 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete auditory biofeedback training
Number of subjects: 22
Study 33370408 — intervention group
Group type: COMPARATOR
Intervention: Discrete visual biofeedback training
Number of subjects: 22
Study 35187770 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 808
Study 35187770 — intervention group
Group type: COMPARATOR
Intervention: Originator insulin glargine (IGlar [Lantus®])
Number of subjects: 808
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with antepartum hemorrhage
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with pregnancy-induced hypertension
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates from multiple pregnancies
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates delivered at health center
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with low birth weight
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with perinatal asphyxia
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with early-onset neonatal sepsis
Number of subjects: 834
Study 33722200 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall neonatal mortality
Number of subjects: 834